Aug 8, 2023 7:00 am EDT Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
Aug 3, 2023 7:00 am EDT Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment
Aug 2, 2023 6:30 am EDT Let There Be Light: A spotlight on Kiora’s Flagship Product, KIO-301, which Aims to Restore Vision for Patients with a Rare Inherited Retinal Disease
Aug 1, 2023 7:00 am EDT Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
Jul 5, 2023 7:00 am EDT Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
Jun 15, 2023 7:00 am EDT Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
Jun 6, 2023 4:30 pm EDT Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Jun 2, 2023 8:30 am EDT Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
May 9, 2023 7:00 am EDT Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments